Medexus Pharmaceuticals (TSE:MDP) Sets New 52-Week High – Still a Buy?

Medexus Pharmaceuticals Inc. (TSE:MDP) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as C$3.78 and last traded at C$3.54, with a volume of 58690 shares trading hands. The stock had previously closed at C$3.50.

Medexus Pharmaceuticals Stock Performance

The firm has a market capitalization of C$116.60 million, a price-to-earnings ratio of -180.50 and a beta of 0.42. The business has a fifty day moving average price of C$3.01 and a 200 day moving average price of C$2.86.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.